BDBM454198 US10717708, Example 174::US11186544, Example 174::US11530183, Example 174

SMILES NC(=O)c1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(F)cc2)C1=O

InChI Key InChIKey=QFLVSTGHVZRVMH-UHFFFAOYSA-N

Data  8 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 454198   

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  450nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  900nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/21/2021
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  450nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  900nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  450nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2022
Entry Details
Go to US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  900nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2022
Entry Details
Go to US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  450nMAssay Description:Agonist activity at human FPR2 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed
TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  900nMAssay Description:Agonist activity at human FPR1 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2024
Entry Details
PubMed